These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36622786)

  • 21. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
    Hartnell F; Brown A; Capone S; Kopycinski J; Bliss C; Makvandi-Nejad S; Swadling L; Ghaffari E; Cicconi P; Del Sorbo M; Sbrocchi R; Esposito I; Vassilev V; Marriott P; Gardiner CM; Bannan C; Bergin C; Hoffmann M; Turner B; Nicosia A; Folgori A; Hanke T; Barnes E; Dorrell L
    Front Immunol; 2018; 9():3175. PubMed ID: 30713538
    [No Abstract]   [Full Text] [Related]  

  • 22. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.
    Xing Z; McFarland CT; Sallenave JM; Izzo A; Wang J; McMurray DN
    PLoS One; 2009 Jun; 4(6):e5856. PubMed ID: 19516906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen.
    Sheerin D; Dold C; O'Connor D; Pollard AJ; Rollier CS
    BMC Genomics; 2021 Oct; 22(1):777. PubMed ID: 34717548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice.
    Chunling M; Kun Y; Jian X; Jian Q; Hua S; Minsheng Z
    Intervirology; 2006; 49(5):307-18. PubMed ID: 16809936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.
    Jordan E; Kabir G; Schultz S; Silbernagl G; Schmidt D; Jenkins VA; Weidenthaler H; Stroukova D; Martin BK; De Moerlooze L
    J Infect Dis; 2023 Oct; 228(8):999-1011. PubMed ID: 37079393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
    Fu YH; He JS; Wang XB; Zheng XX; Wu Q; Xie C; Zhang M; Wei W; Tang Q; Song JD; Qu JG; Hong T
    Biochem Biophys Res Commun; 2010 Apr; 395(1):87-92. PubMed ID: 20350532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
    Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ
    PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
    Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
    PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prime-boost vectored malaria vaccines: progress and prospects.
    Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
    Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
    Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
    JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.
    Luo S; Zhang P; Liu B; Yang C; Liang C; Wang Q; Zhang L; Tang X; Li J; Hou S; Zeng J; Fu Y; Allain JP; Li T; Zhang Y; Li C
    Emerg Microbes Infect; 2021 Dec; 10(1):1002-1015. PubMed ID: 33993845
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
    Betts G; Poyntz H; Stylianou E; Reyes-Sandoval A; Cottingham M; Hill A; McShane H
    PLoS One; 2012; 7(12):e50447. PubMed ID: 23284637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
    Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
    Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenovirus vectored vaccines.
    Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
    Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.